RTCure logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 9
Grant agreement number
777357

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
6 000 000
EFPIA in kind
6 625 000
Other
1 221 866
Total Cost
13 846 866

Summary

Rheumatoid arthritis (RA) occurs when the immune system attacks the joints. Symptoms include painful, swollen joints, stiffness, and fatigue, all of which affect patients’ quality of life. Although RA treatments exist, many patients still struggle to keep their condition under control and many experience unpleasant and sometimes serious side effects of their treatment. Furthermore, there are currently no approved drugs for the early phases of RA.

The RTCure project aims to develop knowledge and tools to aid in the development of treatments for people in the earliest stages of the disease as well as those at risk of developing it. As such, the team will develop and validate new methods to identify people at high risk for RA and tools to monitor the progress of the disease. They will also validate methods to monitor immune tolerance treatments; highly-targeted medicines that stop the immune system’s attacks on the joints while ensuring the immune system remains able to fight off infections.

In the long term, the project hopes that its findings will deliver treatments capable of preventing the disease in those at risk of RA, and curing it in people who are still in the early stages of the disease.

Participants Show participants on map

EFPIA companies
  • Bristol-Myers Squibb Company Corp, Princeton, NJ, United States
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
  • Fondazione Per L'Istituto Di Ricerc A In Biomedicina, Bellinzona, Switzerland
  • Karolinska Institutet, Stockholm, Sweden
  • King'S College London, London, United Kingdom
  • Medizinische Universitaet Wien, Vienna, Austria
  • Semmelweis Egyetem, Budapest, Hungary
  • The University Of Birmingham, Birmingham, United Kingdom
  • The University Of Queensland, St Lucia, Australia
  • Universitatsklinikum Erlangen, Erlangen, Germany
  • University Of Glasgow, Glasgow, United Kingdom
  • University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Anocca AB, Karlskrona, Sweden
  • Apitope International Nv, Diepenbeek, Belgium

CONTACT

Project coordinator
Lars KLARESKOG
KAROLINSKA INSTITUTET
lars.klareskog[at]ki.se
Project leader
Fred BARIBAUD
JANSSEN
FBaribau[at]its.jnj.com